Magnetic Resonance Imaging-Guided Thrombolysis (0.6 mg/kg) Was Beneficial for Unknown Onset Stroke Above a Certain Core Size: THAWS RCT Substudy
Kazunori Toyoda, Manabu Inoue, Sohei Yoshimura, Hiroshi Yamagami, Makoto Sasaki, Mayumi Fukuda-Doi, Kazumi Kimura, Koko Asakura, Kaori Miwa, Takao Kanzawa, Masafumi Ihara, Rei Kondo, Masayuki Shiozawa, Masafumi Ohtaki, Kenji Kamiyama, Ryo Itabashi, Toru Iwama, Junya Aoki, Kazuo Minematsu, Haruko Yamamoto, Masatoshi Koga, THAWS trial investigators*, Ban Mihara, Wataru Mouri, Eisuke Furui, Yukako Yazawa, Yukiko Enomoto, Yusuke Egashira, Yusuke Yakushiji, Taizen Nakase, Ryosuke Doijiri, Yasuhiro Ito, Junichiro Suzuki, Yoshinari Nagakane, Eijiro Tanaka, Yasushi Okada, Seiji Gotoh, Shuichi Igarashi, Hideyuki Ohnishi, Hiroyuki Ohnishi, Akira Tsujino, Yohei Tateishi, Shunya Takizawa, Kazunari Homma, Yoshiaki Shiokawa, Rieko Suzuki, Nobuyuki Sakai, Kenichi Todo, Nobuyuki Ohara, Yasuhiro Hasegawa, Naoshi Sasaki, Shuji Arakawa, Masato Osaki, Tsuyoshi Inoue, Yasushi Takagi, Yasuhisa Kanematsu, Shinichi Yoshimura, Yoshikazu Uesaka, Takao Urabe, Masao Watanabe, Toshihiro Ueda, Shoichiro Sato, Toshimitsu Hamasaki, Toshimitsu Hamasaki, Megimi Sakakibara, Takanari Kitazono, Toshiho Ohtsuki, Wataru Shimizu, Takashi Sozu, Teruyuki Hirano, Kohsuke Kudo, Naomi Morita, Ken Kuwahara, Akira Oita, Kazunari Homma, Kenta Seki, Toshihiro Ide, Takashi Okada, Hajime Ikenouchi, Hiromi Ohara, Mihoko Uotani, Kayo Murata, Shoko Kamiyoshi, Haruka Kanai, Azusa Tokunaga, Ai Ito, Kazunori Toyoda, Manabu Inoue, Sohei Yoshimura, Hiroshi Yamagami, Makoto Sasaki, Mayumi Fukuda-Doi, Kazumi Kimura, Koko Asakura, Kaori Miwa, Takao Kanzawa, Masafumi Ihara, Rei Kondo, Masayuki Shiozawa, Masafumi Ohtaki, Kenji Kamiyama, Ryo Itabashi, Toru Iwama, Junya Aoki, Kazuo Minematsu, Haruko Yamamoto, Masatoshi Koga, THAWS trial investigators*, Ban Mihara, Wataru Mouri, Eisuke Furui, Yukako Yazawa, Yukiko Enomoto, Yusuke Egashira, Yusuke Yakushiji, Taizen Nakase, Ryosuke Doijiri, Yasuhiro Ito, Junichiro Suzuki, Yoshinari Nagakane, Eijiro Tanaka, Yasushi Okada, Seiji Gotoh, Shuichi Igarashi, Hideyuki Ohnishi, Hiroyuki Ohnishi, Akira Tsujino, Yohei Tateishi, Shunya Takizawa, Kazunari Homma, Yoshiaki Shiokawa, Rieko Suzuki, Nobuyuki Sakai, Kenichi Todo, Nobuyuki Ohara, Yasuhiro Hasegawa, Naoshi Sasaki, Shuji Arakawa, Masato Osaki, Tsuyoshi Inoue, Yasushi Takagi, Yasuhisa Kanematsu, Shinichi Yoshimura, Yoshikazu Uesaka, Takao Urabe, Masao Watanabe, Toshihiro Ueda, Shoichiro Sato, Toshimitsu Hamasaki, Toshimitsu Hamasaki, Megimi Sakakibara, Takanari Kitazono, Toshiho Ohtsuki, Wataru Shimizu, Takashi Sozu, Teruyuki Hirano, Kohsuke Kudo, Naomi Morita, Ken Kuwahara, Akira Oita, Kazunari Homma, Kenta Seki, Toshihiro Ide, Takashi Okada, Hajime Ikenouchi, Hiromi Ohara, Mihoko Uotani, Kayo Murata, Shoko Kamiyoshi, Haruka Kanai, Azusa Tokunaga, Ai Ito
Abstract
Background and purpose: We determined to identify patients with unknown onset stroke who could have favorable 90-day outcomes after low-dose thrombolysis from the THAWS (Thrombolysis for Acute Wake-Up and Unclear-Onset Strokes With Alteplase at 0.6 mg/kg) database.
Methods: This was a subanalysis of an investigator-initiated, multicenter, randomized, open-label, blinded-end point trial. Patients with stroke with a time last-known-well >4.5 hours who showed a mismatch between diffusion-weighted imaging (DWI) and fluid-attenuated inversion recovery were randomly assigned (1:1) to receive alteplase at 0.6 mg/kg intravenously or standard medical treatment. The patients were dichotomized by ischemic core size or National Institutes of Health Stroke Scale score, and the effects of assigned treatments were compared in each group. The efficacy outcome was favorable outcome at 90 days, defined as a modified Rankin Scale score of 0 to 1.
Results: The median DWI-Alberta Stroke Program Early CT Score (ASPECTS) was 9, and the median ischemic core volume was 2.5 mL. Both favorable outcome (47.1% versus 48.3%) and any intracranial hemorrhage (26% versus 14%) at 22 to 36 hours were comparable between the 68 thrombolyzed patients and the 58 control patients. There was a significant treatment-by-cohort interaction for favorable outcome between dichotomized patients by ASPECTS on DWI (P=0.026) and core volume (P=0.035). Favorable outcome was more common in the alteplase group than in the control group in patients with DWI-ASPECTS 5 to 8 (RR, 4.75 [95% CI, 1.33-30.2]), although not in patients with DWI-ASPECTS 9 to 10. Favorable outcome tended to be more common in the alteplase group than in the control group in patients with core volume >6.4 mL (RR, 6.15 [95% CI, 0.87-43.64]), although not in patients with volume ≤6.4 mL. The frequency of any intracranial hemorrhage did not differ significantly between the 2 treatment groups in any dichotomized patients.
Conclusions: Patients developing unknown onset stroke with DWI-ASPECTS 5 to 8 showed favorable outcomes more commonly after low-dose thrombolysis than after standard treatment. Registration: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT02002325. URL: https://www.umin.ac.jp/ctr; Unique Identifier: UMIN000011630.
Keywords: control group; intracranial hemorrhage; magnetic resonance imaging; plasminogen; tissue-type plasminogen activator.
Source: PubMed